This article was originally published in The Rose Sheet
Executive SummaryNonprofit organization "devoted to conducting open dialogues among various segments of society concerned with problems in toxicology" will hold its 35 annual summer meeting July 12-16 at the Given Institute in Aspen, Colorado. Research Institute for Fragrance Materials' Anne Marie Api, VP of human health sciences, will chair half-day session entitled "Quantitative Risk Assessment for Dermal Sensitization: What's An Acceptable Exposure?" Panel discussion will involve Procter & Gamble's Carsten Goebel, who will speak on the scientific principles of dermal sensitization risk assessment, as well as dermatologist Donald Belsito of the University of Missouri, who will provide a medical perspective, and the Consumer Products Safety Commission's Joanna Matheson, who will offer a regulatory view. Linda Katz from FDA and Alan Andersen, scientific director of the Cosmetic Ingredient Review, also will participate. Other sessions planned for the Toxicology Forum's July meeting include "Manufactured Nanoscale Materials: Carbon Nanotube Toxicology," "NAS Report on Phthalates and Cumulative Risk Assessment: The Task Ahead," and "Can Carcinogenicity Be Predicted by 6- or 12-Month in vivo Toxicology Data? Results from Analysis of a New Pharmaceutical Database.
You may also be interested in...
Updated data from a postmarket study of Abiomed’s Impella RP right-heart pump further supports the device’s safety for a specific patient population.
The new US-Mexico-Canada (USMCA) trade agreement includes language on enhancing regulatory compatibility between the three countries by recognizing quality systems audits performed under the Medical Device Single Audit Program (MDSAP). It also stipulates that each trading partner “consider its resources and technical capacity” in ensuring the safety, effectiveness and quality of devices – and more. Medtech industry advocacy group AdvaMed is praising the deal, reached by the three countries on 10 December.
Novo Nordisk’s CEO talks to Scrip about the promise of glucose-responsive insulin, stem cell therapy, and a diabetes landscape without Sanofi.